Target therapy and governance : the breast cancer PDTA of the Venetian Oncology Network.
Mutational oncology is becoming a fundamental element of diagnostic-therapeutic care pathways and requires new organizational models that allow for the aggregation of administrative, clinical and biomolecular data. From the experience of the Periplo Foundation in measuring the diagnostic and therapeutic care pathways (DTCP) indicators of almost 20 thousand women with breast cancer in five Italian regions, which showed the difficulty of measuring the efficiency of diagnostic-therapeutic care pathways based on the data available in the existing databases, the Foundation hopes for the creation of digital environments built with the aim of showing the greater/lesser efficiency of the health system.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
Recenti progressi in medicina - 112(2021), 12 vom: 20. Dez., Seite 816-820 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Target therapy e governance: il PDTA del tumore della mammella della Rete Oncologica Veneta |
|---|
| Beteiligte Personen: |
Conte, Pierfranco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4408-81-5 |
|---|
| Anmerkungen: |
Date Completed 19.04.2022 Date Revised 19.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1701/3710.37007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334606276 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334606276 | ||
| 003 | DE-627 | ||
| 005 | 20231225224051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1701/3710.37007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334606276 | ||
| 035 | |a (NLM)34924579 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Conte, Pierfranco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Target therapy and governance |b the breast cancer PDTA of the Venetian Oncology Network. |
| 246 | 3 | 3 | |a Target therapy e governance: il PDTA del tumore della mammella della Rete Oncologica Veneta |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2022 | ||
| 500 | |a Date Revised 19.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Mutational oncology is becoming a fundamental element of diagnostic-therapeutic care pathways and requires new organizational models that allow for the aggregation of administrative, clinical and biomolecular data. From the experience of the Periplo Foundation in measuring the diagnostic and therapeutic care pathways (DTCP) indicators of almost 20 thousand women with breast cancer in five Italian regions, which showed the difficulty of measuring the efficiency of diagnostic-therapeutic care pathways based on the data available in the existing databases, the Foundation hopes for the creation of digital environments built with the aim of showing the greater/lesser efficiency of the health system | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a propanoldiaminetetracetic acid |2 NLM | |
| 650 | 7 | |a 4408-81-5 |2 NLM | |
| 650 | 7 | |a Edetic Acid |2 NLM | |
| 650 | 7 | |a 9G34HU7RV0 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Recenti progressi in medicina |d 1948 |g 112(2021), 12 vom: 20. Dez., Seite 816-820 |w (DE-627)NLM000023124 |x 2038-1840 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2021 |g number:12 |g day:20 |g month:12 |g pages:816-820 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1701/3710.37007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2021 |e 12 |b 20 |c 12 |h 816-820 | ||